Perampanel

證據等級: L5

預測適應症: 10 個

Perampanel: From Focal Epilepsy to Visual Epilepsy

One-Sentence Summary

Perampanel is a selective AMPA-receptor antagonist originally used as adjunctive therapy for partial-onset (focal) seizures in epilepsy. The TxGNN model predicts it may also be effective for Visual Epilepsy (a photosensitive reflex-epilepsy subtype), with 3 clinical trials and 20 publications identified — though none of them studies this specific seizure trigger directly.

Quick Overview

Item	Content
Original Indication	Partial-onset (focal) seizures in epilepsy (derived from literature evidence; official TFDA/BfArM label text is a data gap)
Predicted New Indication	Visual epilepsy
TxGNN Prediction Score	99.92%
Evidence Level	L4
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for this candidate is not available in the evidence pack (data gap). Based on the literature collected, perampanel is described as a selective, non-competitive AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist — the first approved antiepileptic drug with this mechanism, reducing glutamate-mediated postsynaptic excitation and showing broad-spectrum anticonvulsant activity across several seizure models (PMID 21635236, 24559052).

Visual (photosensitive) epilepsy is a reflex epilepsy in which seizures are triggered by visual stimuli such as flickering light, and it shares the same underlying cortical hyperexcitability and glutamatergic overactivation seen in focal and generalized epilepsy. Because AMPA-receptor antagonism dampens cortical excitability broadly rather than acting on a specific trigger pathway, it is mechanistically plausible that perampanel could also suppress visually-triggered seizure activity — one trial in the evidence set (NCT03653741) even specifically measured visual evoked potentials (VEP) as an outcome.

That said, none of the 3 clinical trials or 20 publications identified for this candidate specifically studies visual/photosensitive epilepsy as a treatment indication. The trials cover general partial/generalized seizure tolerability, cognition, and EEG/neurophysiology effects, and the literature is dominated by systematic reviews and guidelines on perampanel's general antiepileptic use. Mechanistic plausibility here currently exceeds the directness of the supporting clinical evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03780907	Phase 2	Completed	18	Randomised, double-blind, placebo-controlled study assessing tolerability, safety and PK of perampanel (E2007) in patients with refractory partial or generalised seizures on concomitant AEDs
NCT02900755	Phase 4	Completed	30	Evaluated perampanel's effects on cognition and EEG in patients with epilepsy; general safety/tolerability focus, not visual-trigger specific
NCT03653741	Phase 4	Completed	12	Evaluated perampanel's effects on neurophysiology tests including EEG, SEP, BAEP and visual evoked potential (VEP) in healthy volunteers

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37059702	2023	Systematic Review (Cochrane)	Cochrane Database Syst Rev	Perampanel add-on for drug-resistant focal epilepsy — general efficacy/safety evidence
36206645	2022	Systematic Review / Meta-analysis	Seizure	Efficacy and safety of perampanel across RCTs in epilepsy
35061214	2022	Systematic Review / Network Meta-analysis	Drugs	Comparison of third-generation ASMs (including perampanel) for adjunctive focal-seizure treatment
37378757	2023	Systematic Review / Network Meta-analysis	J Neurol	ASMs for idiopathic generalized epilepsies
36878742	2023	Systematic Review / Meta-analysis	Brain Dev	Efficacy, tolerability and safety of perampanel in children/adolescents
29898971	2018	Practice Guideline	Neurology	AAN/AES guideline update on new-onset epilepsy treatment with newer AEDs
36150304	2022	Review (trial + real-world evidence)	Epilepsy Behav	Perampanel monotherapy for FOS/GTCS — clinical trial and real-world data
24559052	2014	Review	Expert Opin Drug Discov	Discovery and development of perampanel as first-in-class AMPA antagonist
26111428	2015	Review	Expert Opin Drug Metab Toxicol	PK/PD evaluation of perampanel for partial-onset seizures
41043235	2025	Prospective Multicenter Study	Epilepsy Behav	Perampanel effects on seizures and sleep quality — general epilepsy population

None of the above directly evaluates visual/photosensitive reflex epilepsy as a distinct treatment indication.

Germany Market Information

Perampanel is currently not marketed in Germany (market status: 未上市). No marketing authorizations are on record in this evidence pack (total licenses: 0).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all marked as data gaps in this evidence pack — see DG001, a blocking gap for S1 safety review.)

Conclusion and Next Steps

Decision: Hold

Rationale: Perampanel's AMPA-receptor antagonist mechanism is mechanistically plausible for visual/photosensitive epilepsy, but no clinical trial or publication in the current evidence set specifically evaluates this seizure subtype — all trials and literature concern general focal/generalized epilepsy use. Combined with the drug being unmarketed in Germany and lacking basic label/safety data, the evidence does not yet support proceeding.

To proceed, the following is needed:

Disease-specific evidence for visual/photosensitive epilepsy (e.g., photoparoxysmal-response EEG studies, provocation trials)
Official TFDA/BfArM label data — warnings, contraindications, DDI (blocking gap DG001)
Confirmed mechanism of action documentation from DrugBank (DG002)
Clarification of regulatory/market pathway before any development decision, given current unmarketed status in Germany
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.